We have just launched our AI-enabled Route Scouting Service, which aims to streamline synthetic route identification for novel APIs by combining our global chemical supply chain intelligence and in-house expertise with AI technology from Elsevier.

bit.ly/3xXcMsK

Today we published our 2023 Annual Report and 2023 Sustainability Report. To learn more, visit: bit.ly/4afL9cE

Wolfgang Wienand has been appointed as our new Chief Executive Officer (CEO) and will join Lonza this summer. Wolfgang is currently CEO of Swiss CDMO Siegfried, a role he has held since 2019.

bit.ly/3TEsosp

We have expanded our service offering for spray-drying of proteins for pulmonary delivery. The new offering provides clinical and commercial manufacturing services from Lonza’s Bend (US) site, home to Lonza’s Center of Excellence for respiratory delivery.

bit.ly/3xaNWoW

This morning, we announced that we have signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, California (US) from Roche for USD 1.2 billion subject to regulatory approvals.

Read more: bit.ly/4ahVWmg

'Regional delivery will be transformative for the treatment of Crohn's disease' In this #GENEGUTexplains , Dr. Vincent Jannin (Lonza) and Prof. Brendan Griffin (UCC Pharmacy School) explain the concept of #regionaldelivery and why it is crucial for GENEGUT. Watch the video below 👇

We have entered into a collaboration with Oxford Nanopore, a company delivering a new generation of nanopore-based molecular sensing technology.

Read more: bit.ly/4bisUo4

We are proud to announce we have secured an industry-first, renewable power agreement in China together with four global health companies AstraZeneca, Novartis, Novo Nordisk, Roche and renewable energy leader Envision Energy.

Learn more: bit.ly/3vEcjdQ

We have just launched the TheraPRO® CHO Media System, a new cell culture platform that simplifies processes and optimizes productivity and protein quality when used with GS-CHO cell lines.

Read more: bit.ly/3Q28nfi

We have entered a collaboration with Vertex to support the manufacture of its portfolio of T1D investigational cell therapies, including process development and scale-up, as well as co-investing to build a dedicated new facility in Portsmouth, NH.

bit.ly/46knWoe

Lonza's Virtual Power Purchase Agreement with IGNIS will produce energy equal to Lonza’s electricity needs across Switzerland and the EU. It marks an important step in our ambition to source all power from renewable sources by 2025. bit.ly/3J4ry3I #AHealthierWorld

Lonza has aquired Synaffix, an innovative biotech company focused on antibody-drug conjugates. The acquisition will further strengthen our bioconjugates offering by integrating the proprietary Synaffix technology platform and R&D capabilities:
bit.ly/45DYtWs

Recently, Lonza’s Deanna Mudie and John DiBella from Simulations Plus discussed Lonza's new PBPK modeling software for mitigating absorption risks in early drug development.

To find out more, view the on-demand webinar: lonza.com/knowledge-cent…

#LonzaSM #PBPK #WeWorkAsOne

In our Q1 Qualitative Update, we reported performance in line with our 2023 Full-Year trajectory.

Operations commenced in two new facilities in Visp (CH), while construction began at the facility in Stein (CH).

Read more here: bit.ly/3HZi4pY

Our #cellandgene expert Behnam Ahmadian Baghbaderani will be delivering a presentation at the iPSC Manufacturing Summit in Boston this week. He is looking forward to networking with peers along with our colleagues Elaine Rihn and Marcos Langtry who will also be attending.

At CPHI North America, Deanna Mudie and Josh Marsh will be presenting on how PBPK models can be combined with a range of other tools to highlight potential problems with absorption at an early stage.

Join us on Tuesday, April 25th, at 10am in room 201A.

#LonzaSM #WeWorkAsOne

Lonza's Deanna Mudie and John DiBella from Simulations Plus will be hosting a webinar on April 27 to discuss how PBPK modelling can identify and mitigate absorption risk in early drug development.

Join us at 11am EDT:
event.on24.com/wcc/r/4123022/…

#LonzaSM #PBPK #WeWorkAsOne

Lonza will be exhibiting at CPHI North America from 25-27 April. Visit our team at Booth #459 to discuss your project requirements. Two of our scientists will also be speaking about PBPK modeling at the conference on the Tuesday morning.

#LonzaSM #SmallMolecules #WeWorkAsOne

We are collaborating with ABL Bio, a pioneering Korean biologics company with a focus on bispecific antibodies for immuno-oncology and neurodegenerative diseases, to support the development and manufacturing of ABL Bio's new bispecific antibody product.

bit.ly/3ZFRqrZ

In a recent webinar, Abhijeet Sinha, talked about the importance of solid form services as a bridge between drug substance and drug product when developing a new drug.
You can view the on-demand presentation here: go2.lonza.com/mkform-sv-smm-…

#LonzaSM #SolidFormServices #WeWorkAsOne